Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19

Br J Clin Pharmacol. 2021 Mar;87(3):1589-1590. doi: 10.1111/bcp.14476. Epub 2020 Jul 17.

Ricardo Peña-Silva^{1

2}, Stephen B Duffull³, Andrew C Steer^{4

5

6}, Sandra X Jaramillo-Rincon^{1

7}, Amanda Gwee^{4

5

6}, Xiao Zhu³

¹ School of Medicine, Universidad de los Andes, Bogotá, Colombia.
² Lown Scholars Program, Department of Global Health and Population, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA.
³ Otago Pharmacometrics Group, School of Pharmacy, University of Otago, Dunedin, New Zealand.
⁴ Department of General Medicine, The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia.
⁵ Department of Paediatrics, The University of Melbourne, Parkville, Victoria, Australia.
⁶ Murdoch Children's Research Institute, Parkville, Victoria, Australia.
⁷ Department of Anesthesiology, Clínica de Marly, Bogotá, Colombia.

No abstract available

Publication types